A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

• Drug: Treatment A
  
  PF-00258210 220 µg using inhaler A
• Drug: Treatment B
  
  PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
• Drug: Treatment C
  
  PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
• Drug: Treatment D
  
  PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
• Drug: Treatment E
  
  PF-00258210 220 µg using inhaler B

• Experimental: Treatment A
  
  Intervention: Drug: Treatment A
• Experimental: Treatment B
  
  Intervention: Drug: Treatment B
• Experimental: Treatment C
  
  Intervention: Drug: Treatment C
• Experimental: Treatment D
  
  Intervention: Drug: Treatment D
• Experimental: Treatment E
  
  Intervention: Drug: Treatment E

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive

Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
• A positive urine drug screen
• Pregnant or nursing females